De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Beam Therapeutics Beheer
Beheer criteriumcontroles 4/4
De CEO Beam Therapeutics' is John Evans, benoemd in Apr2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.28M, bestaande uit 10.9% salaris en 89.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.18% van de aandelen van het bedrijf, ter waarde $ 22.94M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 4.4 jaar.
Belangrijke informatie
John Evans
Algemeen directeur
US$6.3m
Totale compensatie
| Percentage CEO-salaris | 10.9% |
| Dienstverband CEO | 7.5yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 5.1yrs |
| Gemiddelde ambtstermijn bestuur | 4.4yrs |
Recente managementupdates
Recent updates
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$143m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$285m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$134m |
| Mar 31 2019 | n/a | n/a | -US$124m |
| Dec 31 2018 | US$4m | US$441k | -US$117m |
Compensatie versus markt: De totale vergoeding ($USD 6.28M ) John } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
John Evans (46 yo)
7.5yrs
Tenure
US$6,280,099
Compensatie
Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2020. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$6.28m | 1.11% $ 20.5m | |
| President | 4.8yrs | US$2.79m | 0.13% $ 2.5m | |
| Senior VP | 5.5yrs | US$2.28m | 0.055% $ 1.0m | |
| Chief Medical Officer | 3.6yrs | US$2.55m | 0.0017% $ 32.0k | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Co-Founder | no data | geen gegevens | geen gegevens | |
| Senior VP of Finance & Treasurer | no data | geen gegevens | 0.0083% $ 153.4k | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 1.6yrs | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 7.2yrs | geen gegevens | geen gegevens | |
| Chief Manufacturing Officer | no data | geen gegevens | geen gegevens |
5.1yrs
Gemiddelde duur
56.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BEAM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | no data | US$6.28m | 1.11% $ 20.5m | |
| Independent Director | 2.9yrs | US$435.22k | 0% $ 0 | |
| Independent Lead Director | 6.4yrs | US$465.22k | 0.022% $ 398.1k | |
| Independent Director | 5yrs | US$450.22k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$447.72k | 0% $ 0 | |
| Independent Director | less than a year | US$772.68k | geen gegevens | |
| Independent Director | 5.9yrs | US$442.72k | 0% $ 0 |
4.4yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BEAM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).